Health officials in Nepal fear leprosy resurgence in the country with prevalence rate reaching 0.94 per cent in 2018.
Leprosy-free status was given to the Himalayan nation after it declared elimination of the disease in 2009. However, that status could be lost if prevalence rate reaches one per cent of total population, Kathmandu Post reported on Thursday.
Experts already fear that this marks the resurgence of the disease in Nepal. The percentage could be more, an official said, as the current given figures have been derived just from preliminary data.
The Leprosy Control and Disability (LCD) section of Epidemiology and Disease Control Division (EDCD) of Department of Health Services said that the prevalence rate was 0.92 and 0.89 in 2017 and 2016, respectively, the news report said.
"It will be a great setback for the country if it loses the status," said Rabindra Baskota, a doctor and chief of the LCD section.
Incubation period of leprosy varies from one to 20 years and diagnosis of more patients could help stop the further spread of the disease, according to him.
"It will take only a couple of years to reach one percent if this upward trend continues," he added.
The prevalence rate is over one per cent in various districts of the Tarai region, Baskota said, adding that the country had received the leprosy eliminated status, after reducing its prevalence rate by 0.77 per cent, in 2009.
Sishir Silwal, a focal person for the leprosy control programme in Gulmi district, said regular review meetings for leprosy, which should be held every four months, has not been held for the last eight months.
Kathmandu Post quoted Bibek Kumar Lal, Director at EDCD, as saying that there is a severe crunch in manpower that hinders proper functioning.
There are only three staff working in the leprosy section and the same team looks after the disability programme, as well, he told the newspaper.
Leprosy, a chronic infectious disease caused by Mycobacterium leprae, is transmitted through nasal secretion or from droplets from the mouth. It affects the skin, peripheral nerves and eyes, leading to disfigurement and nerve damage. The disease is curable with a multi-drug therapy.
--IANS
in
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
